SPOTLIGHT -
Immunotherapy May Lead to Abnormal Thyroid Function in Patients With Cancer
A comprehensive review of patients receiving pembrolizumab has found an incidence of abnormal thyroid function tests as high as 15%.
Cabozantinib Shows Promise in Second- and Third-line Differentiated Thyroid Cancer
Cabozantinib, an oral multikinase inhibitor, showed promise as second- or third-line therapy in patients with advanced differentiated thyroid cancer (DTC).
